This rising trend mirrors the evolution of the pharmaceutical industry in terms of investment and utilisation of novel ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date ...

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in ...

The FDA has extended the review period for the New Drug Application for elamipretide for the treatment of Barth syndrome.

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...

Shares of Replimune Group, Inc. (NASDAQ: NASDAQ:REPL) surged 17% following the announcement that the U.S. Food and Drug ...

The regulatory agency will review MSD’s new drug application (NDA) for Welireg under a Priority Review, with a Prescription ...

The agencies are charged with making decisions that touch the lives of every American and are the source of crucial ...

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The FDA has accepted for review the New Drug Application for plozasiran for the treatment for familial chylomicronemia syndrome.